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Abstract
DQ2 is a surface receptor of class II MHC exposed on APC immune-competent 
cells. Its function is to recognize non-self-antigens and present them to CD4+ 
T-helper lymphocytes, which activate cytokine <21> production and control 
antibody production and cell response. The activation of T lymphocytes by peptides 
derived from gluten proteins and the production of antibodies directed against tTG 
in tissues where it is localized is the basis of the etiopathogenesis of celiac disease 
(CD). CD is frequently associated with the presence of specific HLA system genes 
encoding heterodimers DQ2 and DQ8, identifiable by the DQA1*0501/DQB1*0201 
or DQA1*0501/DQB1*0202 and DQB1*0302 alleles. DQ2 is also associated with 
genetic, endocrinological and neurological diseases such as: type 1 diabetes, 
thyroiditis, pancreatitis and multiple sclerosis. Interactions between DQ2 and T 
lymphoma have also been demonstrated. The correlation between autoimmune 
diseases in patients with CD and therefore DQ2 is much more frequent than in 
healthy subjects.
Keywords: HLA-DQ2, DQ2 isoforms, DQ2 and celiac disease, DQ2 and diseases,  
T helper lymphocytes
1. Introduction to HLA-DQ2 structure and localization
HLA-DQ2 antigen is a surface receptor of antigen-presenting cells (APC), it is 
composed of two polypeptide subunits: the α chain (of 32–34 kD) and the β chain 
(of 29–32 kD) [1]. Each one presents a peptide-binding domain, an Ig-like domain, 
and a transmembrane region with a cytoplasmic tail (Figure 1). These structures 
are bind by non-covalent association leadings. Unlike Major Histocompatibility 
Complex (MHC) class I molecules, both polypeptide chains are encoded by genes in 
the HLA-DQ regions strictly located on chromosome 6 (Figure 2). The pocket for 
the bond with the peptide is constituted for half by one chain and half by the other; 
each one contributes with an α-helix and 4 filaments of the β sheet.
In the extracellular portion, each chain has an Ig domain (α2 and β2) of which, 
β2 contains the binding site for lymphocyte helper CD4+. In HLA-DQ2 both the 
α-chains and the β-chains are polymorphic, as a result, unique DQ molecules can be 
formed, with α- and β-chains encoded on the same chromosome (encoded in cis) or 
on opposite chromosomes (encoded in trans). However, evidence suggests that not 
every α- and β-chain pairing will form a stable heterodimer. It is generally consid-
ered that alleles of DQα- and DQβ-chains pair up predominantly in cis rather than 
in trans. However, the occurrence of trans-encoded HLA class II molecules is well 
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documented in the literature, such as in the case of type 1 diabetes (T1D), where the 
trans encoded HLA molecules may play a role in pathogenesis [4].
Each MHC molecule has only one antigen pocket that can bind one peptide at 
once, but different peptides at different times. Peptides that can bind to MHC-II 
molecules reach 30 or more, while class I MHC molecules can accommodate 
peptides with 8–11 amino acids. The peptide–MHC binding is created during its 
Figure 1. 
Label: The structure of the MHC-II molecule [2].
Figure 2. 
Label: Chromosomal origin of HLA class I and class II [3].
3
The Association of HLA-DQ2 with Celiac Disease
DOI: http://dx.doi.org/10.5772/intechopen.95837
assembly and is used to stabilize the complex to allow its expression on the cell 
surface and for this reason, the dissociation rate is very slow. This naturally provides 
a very long half-life that allows T lymphocytes to meet the antigen. Between MHC 
and peptide, a non-covalent connection is formed among the residues in the pocket. 
Once the binding has occurred, the peptide and the water molecules that solubilize 
it fill the pocket, making contact with the walls and the floor that make it up.
T cells activated by class II molecules are CD4+ helper cells that: activate cyto-
kine production, control antibody synthesis, and regulate cellular response. DQ is 
also involved in the common recognition of auto-antigens; the presentation of these 
antigens to the immune system provides tolerance at a young age. When this toler-
ance is lost DQ can be involved in autoimmune diseases such as celiac disease (CD), 
type 1 diabetes, and many others as we will see more details afterward [5].
2. HLA-DQ2 isoforms
As mentioned before, there are many potential DQ isoforms, as a result of the 
combination of cis- and trans haplotypes and those with cis-pairing are more 
common. Typically individuals can produce 4 isoforms, but only HLA-DQ2.5 and 
HLA-DQ2.2 tend to be predominantly represented.
HLA-DQ2.5 is composed of the allele HLA-DQA1*0501 (or DQA1*0505) encod-
ing the alpha chain and the allele HLA-DQB1*0201 (or DQB1*0202) encoding the 
beta chain. HLA-DQ2.2 consists of the HLA-DQA1*02 alpha chain allele and the 
HLA-DQB1*0202 beta chain allele [6].
Very important concerning isoforms is that different subunit matches can cause 
the binding of different foreign or self-antigens. Generally, MHC molecules have 
slots at the pocket level that can interact with specific amino acids or be comple-
mentary to certain amino acid side chains. The importance of polymorphism is 
detected here: only the ability of MHC to bind specifically to a peptide permits it to 
be recognized by lymphocytes and to trigger the immune response to it.
The molecule HLA-DQ2 has a peculiar ligation system with three binding sites, 
preferably for negatively charged residues and different peptide-binding motifs. 
The binding motifs associated with HLA-DQ2 consist of truncated variants of eight 
different peptides with a length of 9–19 amino acids.
Data from the pooled sequencing and the biochemical binding analyses of 
synthetic variants of a ligand indicate that the side chains of amino acid residues at 
relative position P1 (bulky hydrophobic), P4 (negatively charged or aliphatic), P6 
(Pro or negatively charged), P7 (negatively charged) and P9 (bulky hydrophobic) 
are important for binding of peptides to DQ2 (Figure 3).
Computer modeling of the DQ2 with variants of the ligand in the groove sug-
gests that peptides bind to DQ2 through the primary anchors P1, P7, and P9 and 
making additional advantageous interactions using the P4 and P6 positions [8].
2.1 HLA-DQ2.5
DQ2.5 refers to both a protein isoform and a genetic haplotype. DQ2.5 isoform or 
heterodimer is shorthand for the cell surface receptor HLA-DQ α5β2 (Figure 4).
DQ2.5 and the linked DR3 are associated with probably the greatest frequency 
of autoimmune occurrence relative to any other haplotypes. A genome-wide survey 
of markers linked to celiac disease, reveals that the highest linkage is for a marker 
within the DQA1*0501 allele of the DQ2.5 haplotype. The association of DQB1*0201 
is almost as high. Greatly elevating risk is the ability of the DQ2.5 haplotype 
encoded isoforms to increase abundance on the cell surface in DQ2.5 double 
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homozygote. While the frequency of DQ2.5 haplotype is only 4 times higher than 
the general population, the number of DQ2.5 homozygotes is 10 to 20 times higher 
than the general population. Of the approximately 90% of celiacs that bear the 
DQ2.5 isoform, only 4% produce DQ2.5trans and differs slightly, one amino acid, 
from DQ2.5cis.
Multiple copies of the DQ2.5 haplotype do not cause apparent increases of 
severity in celiac disease, but the 25% of celiac patients homozygous DQ2 (DQ2.5/
DQ2) tend to show increases risk of life-threatening complications and more 
severe histological findings. The HLA-DQ2.5 molecule preferentially binds pep-
tides with negatively charged amino acids at anchor positions [10, 11]. Whereas 
gluten peptides contain few negative charges, these charges can be introduced by 
Figure 3. 
Label: Analysis of the HLA-DQ2 protein: (A) the 3D structure; (B) the binding sites; (C) the amino acids 
residues and the α helix and the β sheet domains [7].
5
The Association of HLA-DQ2 with Celiac Disease
DOI: http://dx.doi.org/10.5772/intechopen.95837
the enzyme tissue transglutaminase (tTG) that selectively deamidates glutamine 
residues in gluten peptides [12–14]. DQ2.5cis is the major factor in adaptive immu-
nity by frequency and efficiency in alpha-gliadin presentation and its responses 
can be differentiated from other DQ isoforms. Specifically, this DQ2 heterodimer 
is responsible for presenting the α2-gliadin that most effectively stimulates patho-
genic T-cells.
As mentioned before, the DQ2.5 haplotype is linked to DR3, which is not linked 
to DQ2.2. Using either serotyping or genotyping DQ2.5 can be distinguished from 
DQ2.2 or DQ2.3 [5].
2.2 HLA-DQ2.2
HLA-DQ2.2 is shorthand for the DQ α2β2 heterodimeric isoform (Figure 5). DQ2.2 
homozygotes represent about 1.1% of the celiac population. While HLA-DQ2.5 is 
strongly associated with the disease, HLA-DQ2.2 is not [5].
Whereas the molecular surfaces of the antigen-binding clefts of HLA-DQ2.5 
and HLA-DQ2.2 are very similar, there are important differences in the 
nature of the peptides presented. These peculiarities in peptide motif binding 
cause differences in responding to T cell repertoires and in the disease pen-
etrance [16].
DQ2.2 individuals can mount an antigluten response but bear a lower risk of 
celiac disease. The reason is fewer gluten peptides would bind stably to this HLA 
molecule. The results give insight into processes important for the establishment of 
T-cell responses to antigen in HLA-associated diseases. Patients with celiac disease 
with DQ2.2 have gluten-reactive T cells in their small intestine [17].
Figure 4. 




DQ2.3 is the shorthand for the heterodimeric DQ α3β2 isoform and is encoded 
by the DQA1*03:DQB1*02 haplotype (Figure 6). The receptor coded for the hap-
lotype is a DQ2.3cis isoform, which is genetically linked to DR7 [5]. The gluten 
epitope, which is the only known HLA-DQ2.3-restricted epitope, is preferentially 
recognized in the context of the DQ2.3 molecule by the T-cell clones of a DQ8/
DQ2.5 heterozygous celiac patient.
The DQ2.3 molecule combines the peptide binding signatures of the DQ2.5 and 
DQ8 molecules. This results in a binding motif with a preference for negatively 
charged anchor residues at both the P1 and the P4 positions. In this way, some 
epitopes can be presented even more effectively in the context of the trans-encoded 
Figure 5. 
Label: The crystal structure of HLA-DQ2.2 [15].
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DQ2.3 molecule. This has relevance for understanding how the trans-encoded 
DQ2.3 molecule is predisposing to type 1 diabetes [4].
The analysis of the structure of DQ2.3 together with all other available DQ crys-
tals shows that the P1 pocket in DQ2.3 is significantly different from that of DQ2.5 
due to the polymorphic MHC residues found in this region. Additionally, DQ2.3 
presents a gluten epitope to T-cells much more efficiently than DQ2.5 [4].
3. Other isoforms
DQ2 beta chains can combine with trans chains to other alpha chains. However, 
there is no preference in cis isoforms for DQ2 alpha chains, 4, 7, 8, or 9 bindings 
Figure 6. 
Label: The crystal structure of HLA-DQ2.3 [18].
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to DQ1 alpha chains (DQA1*01). The DQA1*03, *05 chains process nearly identi-
cal alpha chains. The *04 chain can potentially combine with DQ2 to form DQ2.4. 
There is the possibility of DQ2.6 resulting from coupling with DQA1*0601 [5].
4. HLA-DQ2 and celiac disease
Celiac disease is a genetically determined immune-mediated disorder in which 
individuals carrying HLA DQ2 and/or DQ8 haplotypes develop an immuno-
logic response to gluten ingestion that leads to a wide range of clinical signs and 
symptoms.
The Humoral nature, the hereditary and the polygenic CD have great influ-
ence in triggering the disease. The assessment of HLA-DQ2/DQ8 is relevant from 
a diagnostic aspect to detect celiac disease; in fact, about 95% of patients with CD 
present the HLA-DQ2 genotype [19].
In celiac patient inflammatory T cell responses to HLA-DQ2-bound gluten pep-
tides are thought to cause disease. Gluten-reactive T cells can be isolated from small 
intestinal biopsies of celiac patients. T cells derived from the lesion mainly recog-
nize gluten deamidate peptides. There are several distinct T cell epitopes within 
gluten. DQ2 and DQ8 bind the epitopes so that the glutamic acid residues created 
by deamidification are placed in compartments that have a preference for negatively 
charged side chains. Evidence indicates that in vivo deamidation is mediated by the 
enzyme tissue transglutaminase (tTG) that can also cross-link glutamine residues of 
peptides with lysine residues in other proteins, including tTG itself. This can lead to 
the formation of gluten-tTG complexes. These complexes may allow gluten-reactive 
T-cells to provide aid to tTG-specific B-cells through an intramolecular aid mecha-
nism, thus explaining the presence of gluten-dependent tTG autoantibodies which 
is a characteristic feature of active CDs.
5. HLA-DQ2 and celiac disease class risk
Ideally, all patients with CD carry alleles encoding for the DQ2 and/or DQ8 
molecules or at least one chain of the DQ2 heterodimer. The presence of CD in 
the absence of these DQ risk factors is extremely rare. The presence of these 
molecules does not accurately predict that CD will develop, as they are present in 
25–50% of the general population, although the fact that the vast majority of these 
individuals will never develop the disease. About 90% of individuals with CD 
carry HLA-DQ2.5, while individuals with CD who do not express these haplotype 
usually express either HLA-DQ2.2 or HLA-DQ8; very few coding for HLA DQ7.5 
(DQA1*05:05–DQB1*03:01), DQ2.3 or DQ8.5 (DQA1*05–DQB1*03:02).
Differences in CD risk between haplotypes are related to gluten peptide binding 
and subsequent T-cell response. The effect of gene dose is related to the level of 
peptide binding to homozygous and heterozygous HLA-DQ2 and its subsequent 
presentation to T cells. Individuals homozygous for DQ2.5 and DQ8 have an 
increased risk of the disease. Gluten presentation by HLA-DQ2 homozygous was 
superior to HLA-DQ2/non-DQ2 in terms of T cell proliferation and cytokine secre-
tion (Figure 7).
HLA-DQ2.5 predisposes to celiac disease respect to DQ2.2, because the first 
one presents a large repertoire of gluten peptides, whereas the second one presents 
only a subset of these. HLA-DQ2.2 does not predispose to CD unless it is expressed 
in combination with HLA-DQ2.5. Gluten presentation by HLA-DQ2.5/2.2 induces 
intermediate T-cell stimulation. However, individuals homozygous for HLA-DQ2.5 
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Figure 7. 
Label: Haplotypes and different class risk for celiac disease [20].
Figure 8. 
Label: Genotypes and celiac disease prevalence [21].
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or heterozygous HLA-DQ2.2/2.5 have the highest risk of developing CD. In 
HLA-DQ2.5/2.2 heterozygous individuals have properties identical with HLA-DQ2.5 
dimers. In contrast, HLA-DQ2.5/non-DQ2.2 heterozygous individuals have an only 
slightly increased risk (Figure 8).
Considering even more in detail, it has been demonstrated that differences in 
conferred risk associated with CD are the result of the polymorphism in the α chain 
between HLA-DQ2.5 and HLA-DQ2.2.
HLA-DQ2.2 is virtually identical to the peptide-binding properties of HLA- 
DQ2.5. Both are highly homologous except for a single polymorphic residue 
(HLA-DQ2.5-Tyr22α and HLA-DQ2.2-Phe22α). The role of the Phe22α variant in 
HLA-DQ2.2 is to influence peptide binding preferences and to decide how DQ2.2 
TCRs engage the DQ2.2-gluten complex.
Crystal structure studies revealed a docking strategy, where the TCR 
HLA-DQ2.5 gliadin epitopes complexes were notably distinct from the HLA-DQ2.2-
glut TCR complex [22].
HLA-DQ2.5 and HLA-DQ2.2 binds and presents gluten peptides with glutamate 
residues at anchor positions P4, P6, or P7). Three HLA-DQ2.2 epitopes (DQ2.2-
glut-L1, DQ2.2-glia-α1, and DQ2.2-glia-α2) have sequences similar to HLADQ2.5 
binding peptides, with the exception that they all carry serine at P3. As seen for 
HLA-DQ2.5 epitopes, the HLA-DQ2.2 ones display a hierarchy with DQ2.2-glut-L1 
being the epitopes recognized by most T cells [23].
6. HLA-DQ2 and interaction with HLA-DM
HLA-DQ2 is influenced by interaction with Ag presentation cofactors, invariant 
chain (Ii), HLA-DM (DM), a peptide exchange catalyst for MHC class II (Figure 9).
DM can enhance or suppress the presentation of specific MHCII peptide com-
plexes. In general, MHCII–peptide complexes with lower intrinsic stability are DM 
susceptible, but not all high-stability complexes are DM resistant. HLA-DQ2 is 
relatively resistant to DM because DQ2 has a natural deletion in the region involved 
in the interaction with DM, compared with most other alleles.
The role of DQ2/DM concerns interaction in the DQ2-restricted gliadin epitopes, 
relevant to celiac disease, or DQ2-restricted viral epitopes, relevant to host defense. 
DM activity has different consequences on DQ2 presentation of epitopes to T cell 
clones, with suppression of gliadin presentation and enhancement of viral peptide 
presentation. These results imply key differences in DQ2 Ag presentation pathways.
DM-resistant feature of DQ2 likely contributes to the escape of gliadin peptides 
from extensive DM editing. Also, DQ2 has the special ability to stably bind proline-
rich gliadin peptides that use TG2-deamidated residues as DQ2-binding anchors. 
Figure 9. 
Label: Localization of HLA-DM on the MHC class II region [24].
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Together, these unique features of DQ2 may allow gliadin presentation to disease-
driving CD4+ T cells and contribute to the uniquely selective DQ2 presentation of 
DM-sensitive gliadin epitopes.
In contrast, the presentation of DM-resistant epitopes that form more-stable 
complexes with DQ2 likely relies less on the above mechanisms, as DM editing 
positively affects the presentation of these epitopes. The elevation of DM expres-
sion in peripheral APC (particularly during infection) may benefit self-tolerance by 
attenuating the presentation of DM-sensitive epitopes while boosting the presenta-
tion of DM-resistant pathogen-derived epitopes and aiding in host defense [25].
7.  HLA-DQ2 refractory celiac disease (RCD) and enteropathy-associated 
T-cell lymphoma (EATL)
Refractory celiac disease (RCD) is defined by persistent mal-absorptive symp-
toms and villous atrophy despite strict adherence to a GFD for at least 6–12 months 
in the absence of other causes of non-responsive treated celiac disease.
The pathology can be classified as type 1 (normal intraepithelial lymphocyte 
phenotype), or type 2 (defined by the presence of abnormal [clonal] intraepi-
thelial lymphocyte phenotype). RCD 1 usually improves after treatment with a 
combination of aggressive nutritional support, adherence to GFD, and alternative 
pharmacologic therapies. By contrast, clinical response to alternative therapies in 
RCD 2 is less certain and the prognosis is poor. Severe complications such as ulcer-
ative jejunity and Enteropathy T-cell lymphoma (ETL) may occur in a subgroup of 
patients with RCD [26].
ETL is a T-cell non-Hodgkin lymphoma arising in the gastrointestinal tract that 
shows a differentiation of tumor cells toward the phenotype of intestinal intraepi-
thelial T cells. The clinical course of ETL is highly aggressive, with most patients 
dying from the disease within months of diagnosis. Enteropathy T-cell lymphoma 
comprises two morphologically, clinically, and genetically distinct lymphoma enti-
ties: the ETL type 1 and 2.
ETL arises in individuals with the DQA1*0501, DQB1*02 CD-predisposing 
genotype. The HLA typing found in these patients revealed that more than 95% 
have an HLA-DQ2/-DQ8 genotype [27]. Comparing studies of HLA-DQB1 geno-
typing in celiac disease and ETL have detected that the overall HLA-DQB1 geno-
type pattern observed in type 1 ETL closely resembled those for ETL, whereas 
those of type 2 ETL are not significantly different from that of normal Caucasian 
controls.
ETL1 patients show significantly more frequent expression of HLA-DQB1*02 
than the type 2 ones [28]. Lymphoma type 1 may arise and be pathogenetically 
linked to refractory celiac disease by a stepwise acquisition of genetic alterations. 
Contrary given the genetic alterations and HLA-DQB1 genotype patterns, celiac 
disease may not be causal to type 2 ETL. At least 47% of patients with type 2 ETL 
are very likely to never have had celiac disease [29].
The highly significant correlation between HLA-DQ2 homozygosity and the 
development of RCD II and ETL, suggests that the strength of the gluten-specific 
T-cell response in the laminapropria directly or indirectly influences the likeli-
hood of RCD II and lymphoma development. As already mentioned in the chapter, 
also in this case, the higher T-cell proliferation and cytokine secretion induced by 
HLA-DQ2 homozygous APC, than HLA-DQ2 heterozygous APC, may explain the 
strongly increased risk for disease development in HLA-DQ2/DQ2 individuals [30]. 
This would indicate that adherence to a gluten-free diet is particularly important for 
CD patients who are HLA-DQ2 homozygous.
Celiac Disease
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These observations suggest that specific tests, such as those for lymphocyte typ-
ing for T cells, should be indicated in all patients with CD who are not responding 
to a gluten-free diet. The availability of a simple and reliable immune histochemical 
method can make the distinction between CD and RCD feasible. HLA-DQ typing is 
doable and it may be an efficient test to recognize individuals at risk for these condi-
tions with a poor prognosis, particularly now that some evidence has been given to 
support the hypothesis that autologous hematopoietic stem-cell transplantation can 
alter disease progression in severe [29].
8. HLA-DQ2 and liver/gastrointestinal (GI) disease
Liver and gastrointestinal diseases have many etiologies that are poorly under-
stood. Whether due to genetic abnormalities, psychological factors, or other 
environmental variables, functional disorders can be complex and difficult cases 
to resolve. A strongest evidence of an association with DQ2/8 was found in patients 
with functional upper GI disorders [31]. There are several reasons why it may be 
prudent to study DQ2/8 alleles in GI disease outside of celiac disease in fact, evi-
dence suggests that celiac disease may alter the risk of developing irritable bowel 
syndrome (IBS), inflammatory bowel disease (IBD), eosinophilic esophagitis, 
or certain liver diseases. Several studies have directly compared the prevalence 
of the DQ2/8 haplotype in GI disease. These haplotypes may play a role in liver/
digestive disease through pathological mechanisms different from those of celiac 
disease. DQ2/8 contains myriad genes involved in inflammatory processes, such as 
tumor necrosis factor-α, causal mechanisms between these genes, and GI disease 
may exist.
Known immunological associations between IBD and DR7, which is linked to 
both DQ2 and DQ8 haplotype have been established. The relation between DQ2/8 
and IBD/IBS was analyzed in particular in two studies from an Italian and a Danish 
group and both demonstrated that the proportion of IBS was lower among HLA 
DQ2/8 positive individuals. However the Italian group also found that IBD and liver 
diseases were more prevalent among HLADQ2/8 subjects, but it is not confirmed 
in the Danish study. Prior prevalence data though suggest that IBD, particularly 
Crohn’s disease, is lower in individuals with the DQ2/8 linked celiac disease.
IBS has also been linked to HLA DQ2/8 haplotypes and intestinal transit rates 
[31]. Approximately 46% of patients with diarrhea-predominant IBS (IBS-D) 
have accelerated colonic transit. Some patients with IBS report an association 
of symptoms with specific foods, suggesting a role for food hypersensitivity. 
One such food is gluten in the absence of overt celiac disease. The spectrum of 
gluten sensitivity ranges from minimal histological changes such as increased 
intraepithelial lymphocytes without villous atrophy, increased immunoglobulin 
A (IgA) deposits in intestinal villi, gluten-sensitive diarrhea, and immunological 
mucosal response to gluten exclusion in patients with celiac disease. Typically, one 
or more of these findings are seen in individuals who are positive for HLA-DQ2 
or HLA-DQ8. Wahnschaffe et al. demonstrated that, among patients with IBS-D, 
response of diarrhea to a gluten-free diet was influenced by HLA-DQ2 positiv-
ity and the presence of IgG tissue transglutaminase (TTG) antibody in duodenal 
aspirates. Symptom response to gluten withdrawal occurred in 62% of patients 
positive for both HLA-DQ2 and IgG-TTG; in contrast, only 12% of patients negative 
for HLA-DQ2 and TTG-IgG responded; suggesting that symptom generation in this 
subset of patients is immune-mediated. Is demonstrated that patients with IBS-D, 
positive for either HLA-DQ8 or both HLA-DQ2/DQ8 genotypes that are associated 
with gluten sensitivity, have an accelerated colonic transit time [32].
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The HLA DQ2 in association with HLA-DR3 is also associated with another GI 
disease; in fact, this combination is linked with a more rapid progression of primary 
sclerosing cholangitis (PSC) [33].
9. HLA-DQ2 and diabetes
Type 1 diabetes (T1D) is an autoimmune disease attacking pancreatic 
Langerhans islets. The islets are composed of several types of cells: α, β, δ, ε, and 
pancreatic polypeptide (PP). Each type plays a different role in the secretory func-
tion of the pancreas and, among others, α and β cells produce glucagon and insulin, 
respectively. The interplay between these two compounds provides proper glucose 
level administration in blood.
It has been already shown that auto aggression in T1D starts in mutations in the 
MHC system. HLA-DQ molecules have the role to bind and present beta-cell auto-
antigen derived peptides in T1D. The combinations of DR4-DQ8 and DR3-DQ2 
antigens occur in 90% of people with diabetes. However, the homozygous state 
for an allele does not further increase the risk. Indeed it is well established that 
individuals heterozygous for HLA-DQ2 and HLA-DQ8 have almost 5 fold higher 
risk than homozygous to development of T1D [1, 13, 14]. This has been linked to 
the formation of trans dimers between the HLA-DQ2 α chain and the HLA-DQ8 β 
chain (HLA-DQ8 trans) [19, 22, 26, 34]. In particular, the HLA DQ8 trans het-
erodimer confers the highest risk for the development of T1D. This indicates that 
such HLA-DQ trans dimers can bind and present a unique autoantigen derived 
peptide that leads to beta-cell destruction in the pancreas and the development of 
T1D [35].
Juvenile diabetes has a high association with DQ2.5. A combination of DQ2.5 
and DQ8 significantly increases the risk of type 1 onset of adult diabetes, while the 
presence of DQ2 with DR3 reduces the age of onset and severity of the autoimmune 
disease.
The formation of trans encoded molecules DQ8.5 (DQA1*05:01/DQB1*03:02) 
and DQ2.3 (DQA1*03:01/DQB1*02:01), which could present one or a few specific 
diabetogenic epitopes to CD4+ T-cells, possibly inducing an immune response that 
leads to the destruction of insulin-producing pancreatic β islet cells [12]. A strong 
argument for the involvement of the DQ2.3 heterodimer in type 1 diabetes comes 
from trans racial gene mapping studies that have found that this heterodimer, which 
is typically found in the trans configuration among Caucasian subjects, exists and is 
over-represented in the cis configuration among type 1 diabetes patients of African 
origin [16, 17]. The increased diabetes risk of the African DQ2.3 (DQA1*03:01/
DQB1*02) carrying DR7 haplotype is contrasted by a protecting effect of the DQ2.2 
(DQA1*03:01/DQB1*02) carrying DR7 haplotype of European origin [17].
Patients with homozygous type 1 DQ2 diabetes have a marked prevalence of IgA 
anti-transglutaminase autoantibodies. The great excess of positive transglutaminase 
autoantibodies among homozygous DQ2 diabetics is related to both the presence 
of DQ2 and its addition to all genetic or environmental factors associated with type 
1 diabetes. These additional factors may be related to abnormalities in mucosal 
immunity that increases the risk of both type 1 diabetes and celiac disease.
Type 1 diabetes is an autoimmune disease attacking pancreatic Langerhan’s islet. 
The islet is composed of several types of cells: α, β, δ, ε, and pancreatic polypeptide 
(PP). Each type plays a different role in the secretory function of the pancreas and, 
among others, α and β cells produce glucagon ad insulin, respectively [36]. Interplay 




It has been already shown that auto aggression in T1D starts in mutation in the 
MHC system. HLA-DQ molecules have the role to bind and present beta cell auto-
antigens derived peptides in T1D. The combinations of DR4-DQ8 and DR3-DQ2 
antigens occur in 90% of people with diabetes. However, the homozygous state for 
an allele does not further increase the risk. It is well established that individuals het-
erozygous for HLA-DQ2 and HLA-DQ8 have an almost 5 fold higher risk than those 
who are homozygous for either of the DQ variants for the development of T1D, and 
this has been linked to the formation of trans dimers between the HLA-DQ2 α chain 
and the HLA-DQ8 β chain (HLA-DQ8 trans). This indicates that such HLA-DQ 
trans dimers can bind and present a unique auto antigen-derived peptide that leads 
to beta-cell destruction in the pancreas and the development of T1D. In particular, 
HLA DQ8 trans heterodimer confers the highest risk for the development of T1D.
Indeed diabetes has a high association with DQ2.5. A combination of DQ 2.5 
and DQ8 significantly increases the risk of type 1 onset of adult diabetes, while the 
presence of DQ2 with DR3 reduces the age of onset and severity of the autoimmune 
disease.
The formation of trans encoded molecules DQ8.5 (DQA1*05:01/ DQB1*03:02) 
and DQ2.3 (DQA1*03:01/DQB1*02:01), which could present one or a few specific 
diabetogenic epitopes to CD4+ T cells, possibly inducing an immune response that 
leads to the destruction of insulin-producing pancreatic β islet cells. Moreover, 
a strong argument for the involvement of DQ2.3 heterodimer in type 1 diabetes 
comes from transracial gene mapping studies that have found that this heterodimer, 
which is typically found in the trans-configuration among Caucasian subject, exists 
and is over-represented in the cis configuration among type 1 diabetes patients of 
African origin. The increased diabetes risk of the Africans DQ2.3 carrying DR7 
haplotype is contrasted by a protecting effect of the DQ2.2 carrying DR7 haplotype 
of European origin, speaking to the functional importance of α chain in the DQ2.3 
molecule.
Patients with homozygous type 1 DQ2 diabetes have a marked prevalence of IgA 
anti-transglutaminase autoantibodies. The great excess of positive transglutaminase 
autoantibodies among homozygous DQ2 diabetics is related to both the presence 
of DQ2 and its addition to all genetic or environmental factors associated with type 
1 diabetes. These additional factors may be related to abnormalities in mucosal 
immunity that increases the risk of both type 1 diabetes and celiac disease. In T1D 
the risk associates with the HLA-DQ2/8 heterozygous haplotype was found to be 
increased compared with homozygous HLA-DQ2 or HLA-DQ8 individuals, suggest-
ing an epistatic or synergic effect [37].
10. HLA-DQ2 and thyroid disease
The term autoimmune thyroid disease (AITDs) encompasses several different 
entities characterized by varying degrees of thyroid dysfunction and the presence 
of serum auto-antibodies against thyroid tissue-specific components, such as 
thyroglobulin (TG) and thyroid peroxidase (TPO) [34].
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are AITDs with differ-
ent physiopathology, being traditionally regarded as two different disease entities. 
More recent views, in contrast, have considered the hypothesis that there might be a 
continuum between HT and GD.
Genes of, or closely associated with, the HLA complex are assumed to contribute 
to the genetic predisposition to AITDs. Genetics plays a prominent role in both 
the determination of thyroid hormone and thyrotropin (TSH) concentrations and 
susceptibility to autoimmune thyroid disease. Heritability studies have suggested 
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that up to 67% of circulating thyroid hormone and TSH concentrations are geneti-
cally determined, suggesting a genetic basis for narrow intra-individual variation in 
levels [34]. Until today the mechanisms leading to thyroid autoimmunity are largely 
unknown.
In 30%–40% of healthy individuals, DQ2, and DQ8 are associated with diseases 
such as Hashimoto’s Thyroiditis. In patients with a CD instead, autoimmune thyroid 
disease was observed in 14% and 30.3% in adults, while thyroid abnormalities were 
described in 37.6% and 41.1% in pediatric age.
Noteworthy was the presence of high titers of serum TPO antibodies [11] and 
serum TG antibodies [12] in the celiac pediatric patients without a gluten-free diet 
(GFD), these values were reported to return to normal after 2 or 3 years on a GFD. 
This finding suggests that these antibodies are gluten dependent.
Furthermore has been analyzed the association between Hashimoto’s thyroiditis 
and celiac disease in the Dutch population and it has been demonstrated that HLA 
DQ2.5 was associated with higher TSH levels. This correlation is not been found 
for the other thyroid markers (TPO, FT4). A reason could be that TSH is a more 
sensitive marker for hypothyroidism, as well as the fact that TSH is a quantitative 
parameter measured in all participants of that study, giving more power to detect 
differences.
More than doubled GD rates are correlated to the genetic association to the 
DR3-DQ2 haplotype [38]. A study of Asian Indian patients with Graves’ disease 
revealed a significant increase in the frequency of HLA-DQW2 as compared to the 
control population [37]. HLA-DQA1*0501 was also shown to be associated with 
GD in a Caucasian family study [37] but, the primary susceptibility allele in GD is 
indeed HLA-DR3 [37]. Further analyses have shown that these variants are almost 
always inherited together in Caucasian populations, so they act as a single genetic 
factor. These haplotypes are among the crucial genetic factors of celiac disease in 
European descendants, confirming a strong connection between gluten intolerance 
and autoimmune thyroid conditions. This theory is confirmed by studies on a large 
UK Caucasian case–control population, which have shown that the contribution of 
the HLA class II region to the genetic susceptibility of Graves’ disease is due to the 
haplotype DRB1*0304-DQB1*02-DQA1*0501, with no independent association of 
any individual allele. However, as a result of strong linkage disequilibrium within 
the MHC region, it is difficult to assess which loci are acting as primary etiological 
determinants. The same HLA haplotype is associated with the large multifunctional 
proteasome 2 loci (LMP-2). The LMP molecules are overexpressed in thyrocytes, 
the target cells of Graves’ disease and the LMP genes are found within the MHC 
class II region. The LMP genes may therefore play a role in susceptibility to Graves’ 
disease [39].
11. HLA-DQ2 and dermatitis herpetiformis
Dermatitis herpetiformis (DH) is a chronic, pruritic, papulovesicular skin 
disease of unknown origin. The characteristic rash is symmetrically distributed over 
the extensor surfaces and buttocks and, also, most patients with DH have asymp-
tomatic gluten-sensitive Enteropathy [40].
All patients with DH had typical clinical and histologic features, as well as 
granular deposits of IgA at the dermal-epidermal junction. The gastrointestinal 
lesions are essentially identical to those seen in patients with ordinary CD, although 
less severe and more patchy. A pathophysiologic link between CD and DH has been 
suggested by the observation that the skin lesions of DH as well as the abnormalities 
of the jejunal mucosa regress on a gluten-free diet.
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DH is associated with a markedly increased frequency of the HLA class II anti-
gens DR3 and DQ2. The primary HLA association is HLA-DQ2 (expressed in 100% 
of DH patients), whereas the HLA-DR3 is code in 95% of cases [41]. HLA-DQ8 may 
therefore be a second HLA susceptibility molecule in DH; all the DH patients carry-
ing DQ2 plus a DR4 haplotype also carried DQ8.
An increased frequency of DR3, DQ2 homozygosity, and a slightly increased 
frequency of DR3, DQ2 heterozygosity were found among the DH patients. It is, 
therefore, possible that a gene dosage effect of DQB1*02 may be present also in DH 
patients.
DH and CD both are primarily associated with the same DQ (α1*0501, β1*02) 
heterodimers, and in both diseases most of the few remaining patients not carrying 
this heterodimer instead carry the DQ (α1*03, β1*0302) heterodimers.
In patients where a jejunal biopsy has been performed have been detected abnor-
mal biopsies both among the DQ (α1*0501, β1*02) positive and negative patients. 
No significant differences in the frequency of abnormal biopsies were observed 
between the two groups of patients.
CD and DH have different HLA associations; CD being primarily associated 
with genes in the DQ/DR region, while DH was more strongly associated with genes 
in the complement region. Anyway, the very similar associations in CD and DH to 
the same cis or trans associated DQ2 heterodimer, or the DQ8 heterodimer, can be 
taken as an argument against differences in primary HLA associations in these two 
diseases [41].
12. HLA DQ2 in recurrent pregnancy loss women
Recurrent pregnancy loss (RPL) is diagnosed when three or more consecutive 
spontaneous abortions occur. RPL occurs in about 2–3% of clinically diagnosed 
pregnancies of reproductive-aged women.
At present, accepted etiologies for RPL include parental chromosomal abnor-
malities, untreated hypothyroidism, uncontrolled diabetes mellitus, certain uterine 
anatomic abnormalities, antiphospholipid antibody syndrome, thrombophilias, 
infections, and environmental factors [42].
In RPL women, an increased risk of immune abnormalities, such as increased 
antinuclear antibodies (ANA) and thyroid antibody is been observed [43].
However, in 40% of cases, the cause is unknown.
A significant association between RPL and celiac disease is been demonstrated. 
Various pathogenic mechanisms underlying the pregnancy failure in CD have been 
suggested: among them the ability of anti-transglutaminase antibodies to impair 
the trophoblast invasiveness and endometrial endothelial cells differentiation and 
disrupt early placentation. A higher proportion of individuals HLA DQ2/DQ8 posi-
tive in women with RPL compared to controls is found, (52.6% vs. 23.6%), with 3.6 
times higher odds of DQ2/DQ8 positivity.
Whether a similar mechanism to that of CD can be linked to this obstetric 
complication needs to be investigated. This model might appear a simplification of 
all the complex mechanisms underlying RPL.
The HLA-DQ2/DQ8 alleles by themselves, outside of CD, are found more fre-
quently in RPL women. A possible pathogenic link of HLA-DQ2/DQ8 positivity, in 
presence of exogenous still unknown stimuli, may favor an immune condition with 
detrimental effects during the early stages of pregnancy.
A statistically significant association between HLA-DQ2/DQ8 and ANA positiv-
ity in RPL women is demonstrated. There is a significantly higher prevalence of 
ANA positivity in RPL women compared to control (~ 50% vs. 8.3%–27%).
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ANA are a group of autoantibodies found both in the serum of patients with 
autoimmune and rheumatic diseases and in the general population.
As serological markers, ANA show diagnostic and prognostic significance, while 
their clinical utility in normal individuals is still unclear. Even if many serologically 
positive individuals will never develop an autoimmune disease, others may be in a 
pre-autoimmune state.
Further studies are needed to better understand the possible pathogenic mecha-
nism to this observation; the clinical and therapeutic implications of our observa-
tion to provide a new approach to RPL couples [44].
13. HLA-DQ2 and allergy
HLA class-II alleles are associated with some allergies indicating that these 
alleles might confer susceptibility to the respective allergens. HLA plays a role in 
antigen/allergen presentation and IgE deregulations.
Few studies have associated HLA DQ2/DQ8 with allergy and other ones have 
analyzed the association between HLA class II antigens and the specific IgE 
response to purified allergens. One of these studies found an association between 
DQ8 and have in specific IgE immune response in individuals with a latex allergy, 
while others found DQ2 to be associated with olive pollen. However, the association 
of HLA DQ2/8 with allergy remains unclear.
There is a significant difference between HLA DQ2/8-positive and -negative 
individuals for dust mite allergy.
A significant association between the IgE antibody response to a highly purified 
allergen from olive tree pollen and HLA class II antigens DR7 and DQ2 in Spanish 
patients with seasonal allergic pollenosis is reported. The HLA-DQ2 phenotypic 
frequency is greater in patients with IgE antibodies olive tree pollen compared with 
the control group.
The combined involvement of DR and DQ in the allergen response has only been 
described in the study of reactive T-cell repertoire in a mite sensitized patient. It’s 
identified HLA-DR and DQ restricted T-cell epitopes, one of which can bind to both 
DR and DQ molecules.
These results empathize the importance of genetic factors in the allergic 
response. As described in several reports, antigen-specific and non-specific factors 
are involved in genetic restriction.
Until now none of these factors can be considered as the exclusive determinant 
of the restriction. It is necessary to perform more studies with T-cell lines and 
peptides of this protein to determine which is the main region implicated in this 
response, and clarify this complex response [45].
14. HLA-DQ2 and HIV
Infection with human immunodeficiency virus type 1 (HIV-1) and progres-
sion to acquired immune deficiency syndrome (AIDS) are controlled by both host 
genetic factors and viral factors.
The HLA region controls immune response functions and tissue rejection and 
influences susceptibility to infectious diseases including HIV. There are HLA class 
II alleles associated with susceptibility to and protection from HIV-1 infection and 
that these differences between ethnic groups.
In the HIV+ Caucasian group, a poor prognosis was associated with HLA-DQ2 
and a preferable prognosis was associated with HLA-DQ3.
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The HLA-DQ3 association appears to be linked with the development of 
Toxoplasmic Encephalitis (TE) in AIDS. An association of HLA-DQ2 with the 
occurrence of opportunistic infections in AIDS patients is been confirmed [46]. Of 
interest was the absence of difference in the frequencies of the HLA-DQ2 antigen 
between TE patients and controls.
The development of TE in HIV infected patients is regulated by genes in or near 
the HLA complex and suggests that HLA-DQ typing may help in decisions regard-
ing TE prophylaxis.
An immune response gene in the DQ region may control the progression of HIV 
infection in adults. The rapidly progressive DQ-associated peptide might block the 
progression of HIV if given as a novel vaccine [47].
15. HLA-DQ2 and vaccines
Although DQ2 is associated with vigorous antigluten T cell responses, DQ2 also 
is associated with poor responses to several vaccines and failure to control hepatitis 
virus C and hepatitis virus B.
Studies analyses the association between HLA class II alleles and haplotypes 
with antibody response to recombinant HBsAg vaccination in Iranian healthy adult 
individuals. The results, in parallel with other reports, confirm the association of 
certain HLA class-II alleles with a lack of antibody response to HBsAg vaccine [48].
Discordant HLA/peptide binding and cytokine production patterns observed 
in genetically identical monozygotic twins vaccinated with HBsAg suggest the 
involvement of post genetic and environmental factors influencing the T cell 
repertoire.
However, APC from non-responders can present HBsAg to HLA class 
II-matched T-cells of responders. This indicates that defective HBsAg-specific 
T-cell repertoire rather than APC dysfunction could be involved in vaccination 
failure [49].
Several studies have established significant associations between DQ2, primary 
sclerosing cholangitis, and hepatitis C virus recurrence after transplant. A signifi-
cant relationship between the individual scores of HLA mismatches HLA-DQ2 and 
the recurrence of HCV was observed.
The large proportion of DQ2/8 positive viral hepatitis patients agrees with the 
hypothesis that these haplotypes may be involved in certain liver disease pathogen-
esis. DR3-DQ2 haplotype is the principal risk factor for the disease [50].
Analyses by restriction fragment length polymorphism do not implicate a single 
susceptibility gene at the DQ locus. The unique factor that allows patients with 
autoimmune hepatitis to be distinguished from normal subjects or those with viral 
hepatitis is the DR3-DQ2 haplotype.
The association of DQ2 with suboptimal responses to some viruses raised the 
possibility that its reduced interaction with DM might also lead to the presenta-
tion of moderate-affinity viral peptides, whose unstable binding to DQ2 would 
reduce the surface of the DQ2/peptide complex and compromise CD4+ T cell 
responses [51].
16. HLA-DQ2 and autism
HLA genes also play a role in reproduction, pregnancy maintenance, in parental 
recognition and have been associated with over 100 diseases and disorders includ-
ing autism.
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Autism remained a poorly understood pathology for several decades. It is impor-
tant to note that the diagnostic criteria have been modified over the years to include 
a broader category of symptoms, thus increasing the number of children diagnosed 
with the disorder, now referred to as Autism Spectrum Disorder (ASD) [52].
It has been reported that ASD subjects often have associations with HLA genes 
or haplotypes, suggesting underlying deregulation of the immune system mediated 
by HLA genes.
A significant number of autistic children have serum levels of IgA antibodies 
against the enzyme tissue transglutaminase II (TG2) above normal, and the expres-
sion of these antibodies is linked to the HLA-DR3, DQ2, and DR7, DQ2 haplo-
types [53].
TG2 is expressed in the brain, where it is important in cell adhesion and synaptic 
stabilization.
These children constitute a subpopulation of autistic children who fall within the 
autism disease spectrum, and for whom autoimmunity may represent a significant 
etiological component of their autism.
17. HLA-DQ2 and multiple sclerosis
Multiple sclerosis is a chronic disease in young adults. It is caused by the demy-
elination of the central nervous system cells. It is considered a T-cell-mediated 
autoimmune disease that is likely caused by exogenous events, such as infectious 
agents, in susceptible individuals [54].
Population, family, and twin studies indicate that genetic factors and most 
likely several genes are associated with the disease, but genetic backgrounds as well 
as exogenous or somatic events are required to develop the disease. The strongest 
genetic association with disease among the many candidate genes that were ana-
lyzed was demonstrated for HLA-DR15, HLA-DQ2, and HLA-DQ6 [55]. HLA-class 
II haplotypes such as DR2/DQ6, DR3/DQ2, and DR4/DQ8 show the strongest 
linkage with the disease.
A positive connection of primary progressive MS with DR4-DQ8 and DR1-DQ5 
and an association of “bout onset” MS with DR17-DQ2 is be found, while an HLA 
association with disease severity was not found [56].
It is currently unclear how the expression of a particular HLA class II gene would 
result in susceptibility to develop an organ-specific autoimmune disease.
18. HLA-DQ2 and world frequencies
The HLADQ2 associated disease risk is known to be modified across individuals 
or populations varying in ethnic background, geography, or gender.
The presence of genes coding for DQ2 and DQ8 molecules explains up to 40% 
of the occurrence of celiac disease in European populations. DQ2 is most common 
in Western Europe; higher frequencies are observed in parts of Spain and Ireland. 
In European celiac patients, the frequency of the HLA DQ2 is up by 90% e the HLA 
DQ8 is between five and 10% like was described in Dutch, UK, and Irish cases.
Differences in the frequencies of the HLA genotypes DQ2 and DQ8 in non-Euro-
pean populations have already been described. Patients of Indian origin had a lower 
frequency of HLA DQ2 than those of British origin. Lower frequencies of HLA DQ2 
and higher frequency of HLA DQ8 than Europe have also been described among 
CD patients in the United States (82% DQ2 and 16% DQ8 only) and in Cuba (86% 
DQ2) In Chilean celiac patients the genotype DQ8 predominates. The genotypes 
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DQ2 and DQ8 were present in 93.2% of patients with CD in the Northeast of Brazil. 
The HLA DQ2 was present in 75.6% and DQ8 in 17.8% of these patients.
Another finding from this group is that 79% of the unaffected control families 
carried genotype DQ2 and/or DQ8, which is one of the highest frequencies so 
far described among first-degree relatives. Most studies on HLA among first-
degree relatives found that no more than 59.5% of first-degree relatives in Europe 
presented HLA DQ2 and DQ8. Since the frequencies of genetic markers among 
populations of first-degree relatives reflect and amplify those among the general 
population of which they form part, in this region, a large proportion of the general 
population may carry these markers.
The frequencies of the different isoforms of DQ2 were also analyzed. The 
Eurasian geographic distribution of DQ2.2 is slightly greater than DQ2.5. Compared 
to DQ2.5, the frequency in Sardinia is low, but in Iberia, it is high reaching a maxi-
mum frequency of ~30% in Northern Iberia, and half that in the British.
Cases of DQ2.2 patients with CD without DQ2.5 are in some populations, 
particularly in the south of Europe. It extends along the Mediterranean and Africa 
at relatively high frequency and is found in high frequencies in some Central Asian, 
Mongolians, and Han Chinese. It does not appear to have an indigenous presence 
in the West Pacific Rim and DQ2.2 presence in South-east Asia and Indonesia is 
likely the result of gene flow from India and China in the past. The haplotype shows 
considerable diversity in Africa. The expansion of DQ2.2 into Europe appears to 
have been slightly later. DQ2.5 is generally highest in northern, Icelandic Europe, 
and Basque in northern Spain. Phenotype frequency exceeds 50% in parts of 
Ireland, which overlaps one of three global nodes of the DQ2.5 haplotype in Western 
Europe [57].
19. Conclusion
This work is designed to provide a quick overview of the HLA-DQ2 molecule, 
analyzing the main points such as molecular structure, gene variants, and the 
role played by the molecule in the clinical context; dealing not only with the most 
known autoimmune diseases to which it is linked but also with less known areas of 
development.
This work aimed to offer a new point of view on the subject, although aware of 
having only skimmed the topic, we hope to have offered a starting point for any new 
analysis of the molecule.
This chapter allowed us to analyze HLA in a different context from the most 
known of compatibility in hematopoietic stem cell transplantation, confirming 
once again the enormous complexity of the HLA system and its many facets and 
applications.
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